1. Scrip
  2. >>Business
  3. >>Financing

Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia

 
• By Jessica Merrill

The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.

SC1912_Success_325170179_1200.jpg
Aredlyx's tenapanor was successful in a second Phase III trial • Source: Shutterstock

Ardelyx Inc. expects to file a new drug application with the US Food and Drug Administration for tenapanor for the treatment of hyperphosphatemia in patients on dialysis in mid-2020 after data from a second Phase III trial read out positively. The company announced the positive results of the Phase III PHREEDOM trial testing the first-in-class NH3E inhibitor as a monotherapy on 3 December.

The company is ramping up to launch tenapanor in 2021 independently for hyperphosphatemia, even though it is still seeking a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.